Bayer's 16.7% EPS Drop and €33.6 Billion Debt Burden: Is "On Track" Too Optimistic?

Bayer's half-year update showed sales stability, but earnings and cash flow still dominate the story

Bayer's half-year update did not deliver a simple growth narrative. It delivered a balance-sheet story. The company reported core EPS of €0.95, down 16.7 percent year over year, while Group sales rose 2.2 percent to €10.872 billion. Management still said it was operationally on track, but falling earnings per share and weak cash generation make that claim harder to treat as full validation.

Why the balance sheet matters more here

The more pressing figures are the funding load behind the operating numbers: net financial debt at €33.647 billion and free cash flow declines to minus €371 million, partly due to settlement payments. That combination does not imply immediate survival risk, but it does mean investors should read "on track" more cautiously when profit and cash conversion have not yet improved in step with sales.

Crop Science is helping, but weaker profit conversion in other divisions limits the recovery case

The half-year update is less about whether Bayer can hold things together and more about whether revenue can convert into profit quickly enough to matter for valuation.

Crop Science is doing the heaviest lifting

Bayer said Crop Science higher sales and substantial earnings growth. That is the clearest sign that at least one major segment is converting activity into both top-line and earnings progress. If that trend holds, it gives Bayer a stronger core than a broadly stable but shallowly profitable business.

Pharmaceuticals and Consumer Health are still the weaker links

The rest of the group is not adding the same lift. Bayer reported Pharmaceuticals sales at prior-year level, earnings down and Consumer Health registers slightly higher sales and lower earnings. That is the central problem: stabilizing sales is useful, but it does not justify a higher valuation if margins keep slipping.

The same tension shows up in the broader income statement and cash flow. Bayer said Net income improves to 219 million euros, yet free cash flow still fell to negative territory. That makes the recovery case conditional rather than confirmed.

What would actually support a stronger view

Management also said net financial debt to be lower than originally projected while confirming its currency-adjusted Group outlook. That matters, but it should be treated as a direction of travel, not proof that the turnaround is complete.

The next question is not whether management sounds confident. It is whether the weaker divisions start converting revenue better and whether cash flow improves from the settlement-affected base.

The next real checkpoint is the November results

The next hard checkpoint is Tuesday, November 03, 2026 for Q3 2026 Results. By then, Bayer will need to show whether the August claim of being operationally on track still holds outside the immediate aftermath of the half-year update.

How to read the next update

Treat the November call as a proof test, not a narrative exercise. The optimistic case gets stronger if Crop Science keeps delivering higher sales and substantial earnings growth and if debt continues moving lower than originally projected. The skeptical case holds if Bayer continues to post stable sales but weaker earnings and still struggles to improve cash generation.

My stance

This is not yet a clean recovery call. It looks more like a conditional setup heading into November. The story improves if profit conversion gets better and debt keeps easing. It weakens if sales stability continues without a matching improvement in earnings and cash flow.